Pembrolizumab (+) Berahyaluronidase alfa
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma Recurrent
Conditions
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Trial Timeline
Oct 14, 2024 → Nov 8, 2028
NCT ID
NCT06504394About Pembrolizumab (+) Berahyaluronidase alfa
Pembrolizumab (+) Berahyaluronidase alfa is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma Recurrent. The current trial status is active. This product is registered under clinical trial identifier NCT06504394. Target conditions include Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06504394 | Phase 2 | Active |
| NCT06041802 | Phase 2 | Active |
Competing Products
11 competing products in Classical Hodgkin Lymphoma Recurrent
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 52 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 32 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |
| GEN3017 | Genmab | Phase 1/2 | 38 |